The Na⁺/H⁺ Exchange Inhibitor Cariporide is Washed Out of the Myocardium by Crystalloid Cardioplegia[1] [2]

Abstract

Background: Inhibition of the Na⁺/H⁺ exchanger (NHE) is cardioprotective, but dosage and timing of NHE-inhibitors are critical for their efficacy. We studied the effect of a new dosing regime of the NHE-inhibitor cariporide on myocardial function and damage after cardioplegic arrest (CPA) and determined its myocardial and serum concentrations. Methods: 3 pigs received a bolus of 180 mg cariporide intravenously (i. v.) and were sacrified shortly thereafter to allow measurement of the myocardial concentrations of cariporide. Subsequently, 10 pigs were randomized to receive either i. v. cariporide (bolus followed by an infusion of 40 mg/h) or placebo. Cardiopulmonary bypass was initiated, and the heart was arrested for 60 minutes by infusion of St. Thomas Hospital solution. Left ventricular (LV) function was studied using microsonometry. Myocardial damage was assessed by troponin T. Serum concentrations of cariporide were measured throughout the study, and myocardial concentrations were measured before the end of CPA and 180 minutes thereafter. Results: Cariporide was present in all myocardial specimens (median: 1.4 ng/mg) studied priorly. In the main study, LV function or myocardial damage did not differ significantly between the groups at any time point. Stable serum cariporide concentrations were achieved (3.4 ± 0.5 µg/ml). Cariporide was detectable in only one of the myocardial biopsies obtained before the end of CPA, but 180 minutes thereafter, the myocardial cariporide concentration was 2.5 ± 0.3 ng/mg. Conclusion: We observed no effect of i. v. cariporide on LV function or myocardial damage after cardioplegic arrest. Our data suggest that cariporide is washed out of the myocardium by repeated application of crystalloid cardioplegia. Thus, the mode of delivery also appears to be critical for cardioprotection with NHE-inhibitors.

Animal model - cardioplegia - ischaemia/reperfusion - myocardial protection

References

• 1 Mangano D T. Cardiovascular morbidity and CABG surgery - a perspective: epidemiology, costs, and potential therapeutic solutions.  J Card Surg. 1995;  10 (4 Suppl) 366-368
• 2 Klatte K, Chaitman B, Théroux P. et al . Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release. Results from the Guardian trial.  J Am Coll Cardiol. 2001;  38 1070-1077
• 3 Costa M A, Carere R G, Lichtenstein S V. et al . Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the Arterial Revascularization Therapies Study (ARTS).  Circulation. 2001;  104 2689-2693
• 4 Marso S P, Bliven B D, House J A, Muehlebach G F, Borkon A M. Myonecrosis following isolated coronary artery bypass grafting is common and associated with an increased of long-term mortality.  Eur Heart J. 2003;  24 1323-1328
• 5 Nashef S AM, Roques F, Michel P. et al . European system for cardiac operative risk evaluation (EuroSCORE).  Eur J Cardiothorac Surg. 1999;  16 9-13
• 6 Ferguson Jr T B, Hammill B G, Peterson E D, DeLong E R, Grover F L. A decade of change - risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990 - 1999; a report from the STS National Database Committee and the Duke Clinical Research Institute. Society of Thoracic Surgeons.  Ann Thorac Surg. 2003;  73 480-489
• 7 Piper H M, Meuter K, Schäfer C. Cellular mechanisms of ischemia-reperfusion injury.  Ann Thorac Surg. 2003;  75 S644-S648
• 8 Zimmerman A, Daems W, Hülsman W. et al . Morphologic changes of heart muscle caused by successive perfusion with calcium-free and calcium-containing solutions (calcium paradox).  Cardiovasc Res. 1967;  1 201-209
• 9 Karmazyn M, Gan X T, Humphreys R A, Yoshida H, Kusumoto K. The myocardial Na⁺-H⁺ exchange. Structure, regulation, and its role in heart disease.  Circ Res. 1999;  85 777-786
• 10 Tani M, Neely J R. Role of intracellular Na⁺ in Ca²⁺ overload and depressed recovery of ventricular function of reperfused ischemic rat hearts. Possible involvement of H⁺-Na⁺ and Na⁺-Ca²⁺ exchange.  Circ Res. 1989;  65 1045-1056
• 11 Avkiran M. Rational basis for use of sodium-hydrogen exchange inhibitors in myocardial ischemia.  Am J Cardiol. 1999;  83 10G-18G
• 12 Zeymer U, Suryapranata H, Monassier J P. et al . The Na⁺/H⁺ exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction.  J Am Coll Cardiol. 2001;  38 1644-1650
• 13 Théroux P, Chaitman B R, Danchin N. et al . Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the Guardian trial.  Circulation. 2000;  102 3032-3038
• 14 Weber W, Harnisch L, Jessel A. For the Guardian trial investigators. Lessons learned from a phase III population pharmacokinetic study of cariporide in coronary artery bypass graft surgery.  Clin Pharmacol Ther. 2002;  71 457-467
• 15 Avkiran M. Na⁺/H⁺ exchange inhibitors for cardioprotective therapy: progress, problems and prospects.  J Am Coll Cardiol. 2002;  39 747-753
• 16 Mentzer Jr R M Expedition Study investigators On behalf of the . Late-breaking clinical trials abstracts: Effects of Na⁺/H⁺ exchange inhibition by cariporide on death and nonfatal myocardial infarction in patients undergoing coronary artery bypass graft surgery: The Expedition Study.  Circulation. 2003;  108 2723/3-2723/4
• 17 Glower D D, Spratt J A, Snow N D. et al . Linearity of the Frank-Starling relationship in the intact heart: the concept of preload recruitable stroke work.  Circulation. 1985;  71 994-1009
• 18 Matsubara H, Takaki M, Yasuhara S, Araki J, Suga H. Logistic time constant of isovolumetric relaxation pressure-time curve in the canine left ventricle.  Circulation. 1995;  92 2318-2326
• 19 Karmazyn M, Sostaric J V, Gan X T. The myocardial Na⁺/H⁺ exchanger. A potential therapeutic target for the prevention of myocardial ischemic and reperfusion injury and attenuation of postinfarction heart failure.  Drugs. 2001;  61 375-389
• 20 Klein H H, Pich S, Bohle R M, Wollenweber J, Nebendahl K. Myocardial protection by Na⁺-H⁺ exchange inhibition in ischemic, reperfused porcine hearts.  Circulation. 1995;  92 912-917
• 21 Klass O, Fischer U M, Perez E. et al . Effect of the Na⁺/H⁺ exchange inhibitor eniporide on cardiac performance and myocardial high-energy phosphates in pigs subjected to cardioplegic arrest.  Ann Thorac Surg. 2004;  77 658-663
• 22 Castellá M, Buckberg G D, Tan Z. Blood cardioplegic protection in profoundly damaged hearts: role of Na⁺-H⁺ exchange inhibition during pretreatment or during controlled reperfusion supplementation.  Ann Thorac Surg. 2003;  75 1238-1245
• 23 Garcia-Dorado D, González M A, Barrabés J A. et al . Prevention of ischemic rigor contracture during coronary occlusion by inhibition of Na⁺-H⁺ exchange.  Cardiovasc Res. 1997;  35 80-89
• 24 Hartmann M, Decking U K. Blocking Na⁺-H⁺ exchange by cariporide reduces Na⁺-overload in ischemia and is cardioprotective.  J Mol Cell Cardiol. 1999;  31 1985-1995
• 25 Schertel E R. Assessment of left-ventricular function.  J Thorac Cardiovasc Surg. 1998;  46 (Suppl 2) 248-254
• 26 Cox Jr C S, Sauer H, Allen S J, Buja L M, Laine G A. Sodium/hydrogen-exchanger inhibition during cardioplegic arrest and cardiopulmonary bypass: An experimental study.  J Thorac Cardiovasc Surg. 2002;  123 959-966
• 27 Muraki S, Morris C D, Budde J M. et al . Blood cardioplegia supplementation with the sodium-hydrogen ion exchange inhibitor cariporide to attenuate infarct size and coronary artery endothelial dysfunction after severe regional ischemia in a canine model.  J Thorac Cardiovasc Surg. 2003;  125 155-164
• 28 Corvera J S, Zhao Z Q, Schmarkey L S. et al . Optimal dose and mode of delivery of Na⁺/H⁺ exchange-1 inhibitor are critical for reducing postsurgical ischemia-reperfusion injury.  Ann Thorac Surg. 2003;  76 1614-1622

1 Presented as a moderated poster during the 34th annual meeting of the German Society for Thoracic and Cardiovascular Surgery in Hamburg, Germany, February 13 - 16, 2005

2 Disclosure: Prof. Bartels is a member of the Expedition Trial steering committee and has received fees in this context from Aventis, the manufacturer of cariporide